The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials
Reads0
Chats0
TLDR
The present meta-analysis of four trials supports that NOACs are safe and at least as effective as warfarin in patients with atrial fibrillation and established CAD.Abstract:
Background:Patients with atrial fibrillation and concomitant coronary artery disease (CAD) are at higher risk for myocardial infarction or cardiovascular death, often require antiplatelet therapy a...read more
Citations
More filters
Journal ArticleDOI
JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias
Katsushige Ono,Yu-ki Iwasaki,Masaharu Akao,Takanori Ikeda,K. Ishii,Yasuya Inden,Kengo Kusano,Yoshinori Kobayashi,Yukihiro Koretsune,Tetsuo Sasano,Naokata Sumitomo,Naohiko Takahashi,Shinichi Niwano,Nobuhisa Hagiwara,Ichiro Hisatome,Tetsushi Furukawa,Haruo Honjo,Panayiotis D. Megaloikonomos,Yuji Murakawa,Masahiro Yasaka,Eiichi Watanabe,Takeshi Aiba,Mari Amino,Hideki Itoh,Hisashi Ogawa,Yasuo Okumura,Chizuko Aoki-Kamiya,Jun Kishihara,Eitaro Kodani,Takashi Komatsu,Yusuke Sakamoto,Kazuhiro Satomi,Tsuyoshi Shiga,Tetsuji Shinohara,Atsushi Suzuki,Shinya Suzuki,Yukio Sekiguchi,Satoshi Nagase,Noriyuki Hayami,Masahide Hara,Tadashi Fujino,Takeru Makiyama,Mitsunori Maruyama,Junichiro Miake,Shota Muraji,Hiroshige Murata,Norishige Morita,Hisashi Yokoshiki,Koichiro Yoshioka,Kenji Yodogawa,Hiroshi Inoue,Ko Okumura,Takeshi Kimura,Hiroyuki Tsutsui,Wataru Shimizu +54 more
Journal ArticleDOI
Mendelian randomization study on atrial fibrillation and cardiovascular disease subtypes.
TL;DR: In this paper, the causal role of atrial fibrillation (AF) on ischemic heart disease (IHD), stroke, other cardiovascular disease (CVD) subtypes, type 2 diabetes mellitus (T2DM), and late-onset AD using bi-directional two-sample Mendelian randomization (MR) among people primarily of European descent.
Journal ArticleDOI
Non-vitamin K oral anticoagulants for coronary or peripheral artery disease: a systematic review and meta-analysis of mortality and major bleeding.
Ádám Nagy,Jun H. Kim,Jun H. Kim,Myeong Eun Jeong,Min H. Heo,Alessandro Putzu,Alessandro Belletti,Giuseppe Biondi-Zoccai,Giovanni Landoni +8 more
TL;DR: NoACs reduced all-cause mortality in patients with or at risk for CAD or PAD, even though they increased the risk of major bleeding, and future studies regarding the best doses of NOACs are warranted.
Journal ArticleDOI
Residual Stroke Risk in Atrial Fibrillation.
TL;DR: In this paper, the residual stroke risk in patients with AF and potential therapeutic options for these patients were explored, and a significant proportion of patients were found to remain at high risk despite receiving appropriate dose-adjusted anticoagulation.
Journal ArticleDOI
Incidence and Risk Factors for Residual Adverse Events Despite Anticoagulation in Atrial Fibrillation: Results From Phase II/III of the GLORIA‐AF Registry
TL;DR: The incidence of ischemic stroke was comparable among patients treated with nonvitamin K antagonist oral anticoagulants versus vitamin K antagonist; however, there were differences in the independent predictors between both groups.
References
More filters
Journal ArticleDOI
Meta-Analysis in Clinical Trials*
TL;DR: This paper examines eight published reviews each reporting results from several related trials in order to evaluate the efficacy of a certain treatment for a specified medical condition and suggests a simple noniterative procedure for characterizing the distribution of treatment effects in a series of studies.
Journal ArticleDOI
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher,Larissa Shamseer,Mike Clarke,Davina Ghersi,Alessandro Liberati,Mark Petticrew,Paul G. Shekelle,Lesley A. Stewart +7 more
TL;DR: A reporting guideline is described, the Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols 2015 (PRISMA-P 2015), which consists of a 17-item checklist intended to facilitate the preparation and reporting of a robust protocol for the systematic review.
Ítems de referencia para publicar Protocolos de Revisiones Sistemáticas y Metaanálisis: Declaración PRISMA-P 2015 Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher,Larissa Shamseer,Michael Clarke,Davina Ghersi,Alessandro Liberati,Mark Petticrew,Lesley A. Stewart +6 more
Journal ArticleDOI
Dabigatran versus warfarin in patients with atrial fibrillation
Stuart J. Connolly,Michael D. Ezekowitz,John W. Eikelboom,Jonas Oldgren,Amit Parekh,Janice Pogue,Paul A. Reilly,Ellison Themeles,Jeanne Varrone,Susan Wang,Marco Alings,Denis Xavier,Jun Zhu,Rafael Diaz,Basil S. Lewis,Harald Darius,Hans-Christoph Diener,Campbell D. Joyner,Lars Wallentin +18 more
TL;DR: In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.
Journal ArticleDOI
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.
Larissa Shamseer,David Moher,Mike Clarke,Davina Ghersi,Alessandro Liberati,Mark Petticrew,Paul G. Shekelle,Lesley A. Stewart +7 more
TL;DR: The PRISMA-P checklist as mentioned in this paper provides 17 items considered to be essential and minimum components of a systematic review or meta-analysis protocol, as well as a model example from an existing published protocol.